Advisors Preferred LLC Has $140,000 Stake in GlaxoSmithKline PLC (NYSE:GSK)

Advisors Preferred LLC lowered its stake in GlaxoSmithKline PLC (NYSE:GSK) by 2.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 3,240 shares of the pharmaceutical company’s stock after selling 84 shares during the period. Advisors Preferred LLC’s holdings in GlaxoSmithKline PLC were worth $140,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its stake in shares of GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after buying an additional 2,482,009 shares during the last quarter. Thrivent Financial For Lutherans boosted its stake in shares of GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after buying an additional 1,371,490 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares during the last quarter. Institutional investors and hedge funds own 8.99% of the company’s stock.

Shares of GlaxoSmithKline PLC (GSK) opened at 38.79 on Monday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59. The stock has a market capitalization of $94.80 billion, a PE ratio of 37.51 and a beta of 1.03. The stock has a 50 day moving average of $41.84 and a 200 day moving average of $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. Analysts forecast that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. GlaxoSmithKline PLC’s dividend payout ratio is 197.00%.

WARNING: “Advisors Preferred LLC Has $140,000 Stake in GlaxoSmithKline PLC (NYSE:GSK)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/14/advisors-preferred-llc-has-140000-stake-in-glaxosmithkline-plc-nysegsk.html.

GSK has been the topic of a number of recent research reports. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. GlaxoSmithKline PLC has a consensus rating of “Hold” and a consensus target price of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit